Increased Risk of Herpes Zoster Infection in Patients with Celiac Disease 50 Years Old and Older.
Celiac disease
Herpes zoster
Immunization
Shingles
Vaccine
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
30 May 2024
30 May 2024
Historique:
received:
09
11
2023
accepted:
07
05
2024
medline:
31
5
2024
pubmed:
31
5
2024
entrez:
30
5
2024
Statut:
aheadofprint
Résumé
Celiac Disease (CD) is associated with increased susceptibility to certain bacterial and viral infections. Herpes zoster (HZ) is a viral infection that can be prevented by immunization. In the US, the vaccine is recommended for adults ≥ 50 or ≥ 19 with certain at-risk conditions, not including CD. We aimed to determine if adult patients aged < 50 or ≥ 50 years with CD had a higher risk of developing HZ. We designed a retrospective cohort study. CD was defined as patients with the ICD-10 code for CD and positive Celiac serology. Patients with negative serology and lacking CD ICD-10 codes served as controls. Patients who had HZ before CD diagnosis were excluded. We formed two sub-cohorts, those aged < 50 (cohort 1) and aged ≥ 50 years (cohort 2), and evaluated HZ infection at 10-year follow-up. To account for confounding variables, we performed 1:1 propensity score matching (PSM). Following PSM, cohort 1 had 6,826 CD patients, and cohort 2 had 5,337 CD patients and respective matched controls. After ten years of follow-up, in cohort 1, 62 CD patients developed HZ versus 57 controls, RR: 1.09 (CI: 0.76-1.56, p-value = 0.64). In cohort 2, 200 CD patients developed HZ versus 159 controls, RR: 1.2 (CI: 1.02-1.54, p-value = 0.03). There was no significant difference in the likelihood of getting HZ in CD patients < 50, although CD patients ≥ 50 had a modestly increased risk. Our findings do not support routine early vaccination for HZ in CD, and the vaccine should be offered at age 50.
Sections du résumé
BACKGROUND
BACKGROUND
Celiac Disease (CD) is associated with increased susceptibility to certain bacterial and viral infections. Herpes zoster (HZ) is a viral infection that can be prevented by immunization. In the US, the vaccine is recommended for adults ≥ 50 or ≥ 19 with certain at-risk conditions, not including CD.
AIMS
OBJECTIVE
We aimed to determine if adult patients aged < 50 or ≥ 50 years with CD had a higher risk of developing HZ.
METHODS
METHODS
We designed a retrospective cohort study. CD was defined as patients with the ICD-10 code for CD and positive Celiac serology. Patients with negative serology and lacking CD ICD-10 codes served as controls. Patients who had HZ before CD diagnosis were excluded. We formed two sub-cohorts, those aged < 50 (cohort 1) and aged ≥ 50 years (cohort 2), and evaluated HZ infection at 10-year follow-up. To account for confounding variables, we performed 1:1 propensity score matching (PSM).
RESULTS
RESULTS
Following PSM, cohort 1 had 6,826 CD patients, and cohort 2 had 5,337 CD patients and respective matched controls. After ten years of follow-up, in cohort 1, 62 CD patients developed HZ versus 57 controls, RR: 1.09 (CI: 0.76-1.56, p-value = 0.64). In cohort 2, 200 CD patients developed HZ versus 159 controls, RR: 1.2 (CI: 1.02-1.54, p-value = 0.03).
CONCLUSION
CONCLUSIONS
There was no significant difference in the likelihood of getting HZ in CD patients < 50, although CD patients ≥ 50 had a modestly increased risk. Our findings do not support routine early vaccination for HZ in CD, and the vaccine should be offered at age 50.
Identifiants
pubmed: 38816598
doi: 10.1007/s10620-024-08487-6
pii: 10.1007/s10620-024-08487-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Lebwohl B, Rubio-Tapia A. Epidemiology, presentation, and diagnosis of celiac disease. Gastroenterology 2021;160:63–75. https://doi.org/10.1053/J.GASTRO.2020.06.098.
doi: 10.1053/J.GASTRO.2020.06.098.
pubmed: 32950520
Ludvigsson JF. Mortality and malignancy in celiac disease. Gastrointest Endosc Clin N Am 2012;22:705–722. https://doi.org/10.1016/J.GIEC.2012.07.005.
doi: 10.1016/J.GIEC.2012.07.005.
pubmed: 23083988
Ford A, Chatterjee A, Lyu R, McMichael J, Jansson-Knodell C, Rubio-Tapia A. Increased risk of hospitalization in celiac disease with COVID-19 infection is mitigated by vaccination. Clin Gastroenterol Hepatol. 2023. https://doi.org/10.1016/J.CGH.2023.01.029.
doi: 10.1016/J.CGH.2023.01.029.
pubmed: 37302448
pmcid: 9933522
Mårild K, Fredlund H, Ludvigsson JF. Increased risk of hospital admission for influenza in patients with celiac disease: a nationwide cohort study in Sweden. Am J Gastroenterol 2010;105:2465–2473. https://doi.org/10.1038/AJG.2010.352.
doi: 10.1038/AJG.2010.352.
pubmed: 20823839
Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Lebwohl B. American College of gastroenterology guidelines update: diagnosis and management of celiac disease. Am J Gastroenterol 2023;118:59–76. https://doi.org/10.14309/AJG.0000000000002075.
doi: 10.14309/AJG.0000000000002075.
pubmed: 36602836
Saguil A, Kane S, Mercado M, Lauters R. Herpes Zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2017. 96 656–663. https://pubmed.ncbi.nlm.nih.gov/29431387/ . Accessed 15 Jan, 2023.
Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022. https://doi.org/10.3390/V14020192 .
doi: 10.3390/V14020192
pubmed: 36298705
pmcid: 9609047
Hadley GR, Gayle JA, Ripoll J et al. Post-herpetic neuralgia: a review. Curr Pain Headache Rep 2016;20:1–5. https://doi.org/10.1007/S11916-016-0548-X.
doi: 10.1007/S11916-016-0548-X.
Ludvigsson JF, Choung RS, Marietta EV, Murray JA, Emilsson L. Increased risk of herpes zoster in patients with coeliac disease—nationwide cohort study. Scand J Public Health 2018;46:859–866. https://doi.org/10.1177/1403494817714713.
doi: 10.1177/1403494817714713.
pubmed: 28701089
Herpes zoster shingrix vaccine recommendations | CDC. https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html . Accessed January 15, 2023.
Emilsson L, Lebwohl B, Green PHR, Murray JA, Mårild K, Ludvigsson JF. Mucosal healing and the risk of serious infections in patients with celiac disease. United Eur Gastroenterol J 2018;6:55. https://doi.org/10.1177/2050640617707868.
doi: 10.1177/2050640617707868.
Röckert Tjernberg A, Mårild K, Söderling J et al. Celiac disease and serious infections: a nationwide cohort study from 2002 to 2017. Am J Gastroenterol 2022;117:1675–1683. https://doi.org/10.14309/AJG.0000000000001877.
doi: 10.14309/AJG.0000000000001877.
pubmed: 35973180
Noh KW, Poland GA, Murray JA. Hepatitis B vaccine nonresponse and celiac disease. Am J Gastroenterol 2003;98:2289–2292. https://doi.org/10.1111/J.1572-0241.2003.07701.X.
doi: 10.1111/J.1572-0241.2003.07701.X.
pubmed: 14572581
Costantino A, Michelon M, Roncoroni L et al. Vaccination status and attitudes towards vaccines in a cohort of patients with celiac disease. Vaccines. 2022. https://doi.org/10.3390/VACCINES10081199 .
doi: 10.3390/VACCINES10081199
pubmed: 36560501
pmcid: 9783561
Bledsoe AC, King KS, Larson JJ et al. Micronutrient deficiencies are common in contemporary celiac disease despite lack of overt malabsorption symptoms. Mayo Clin Proc 2019;94:1253–1260. https://doi.org/10.1016/J.MAYOCP.2018.11.036.
doi: 10.1016/J.MAYOCP.2018.11.036.
pubmed: 31248695
Hallert C, Grant C, Grehn S et al. Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years. Aliment Pharmacol Ther 2002;16:1333–1339. https://doi.org/10.1046/j.1365-2036.2002.01283.x.
doi: 10.1046/j.1365-2036.2002.01283.x.
pubmed: 12144584
Gombart AF, Pierre A, Maggini S. A review of micronutrients and the immune system-working in harmony to reduce the risk of infection. Nutrients. 2020. https://doi.org/10.3390/NU12010236 .
doi: 10.3390/NU12010236
pubmed: 32899398
pmcid: 7551403
Nemes E, Lefler É, Szegedi L et al. Gluten intake interferes with the humoral immune response to recombinant hepatitis B vaccine in patients with celiac disease. Pediatrics. 2008. https://doi.org/10.1542/PEDS.2007-2446 .
doi: 10.1542/PEDS.2007-2446
pubmed: 18519462
Leung J, Dooling K, Marin M, Anderson TC, Harpaz R. The impact of universal varicella vaccination on herpes zoster incidence in the united states: comparison of birth cohorts preceding and following varicella vaccination program launch. J Infect Dis 2022;226:S470–S477. https://doi.org/10.1093/INFDIS/JIAC255.
doi: 10.1093/INFDIS/JIAC255.
pubmed: 36265856
Products - Data Briefs - Number 370- July 2020. https://www.cdc.gov/nchs/products/databriefs/db370.htm . Accessed April 1, 2023.
Shingles vaccination: what everyone should know | CDC. https://www.cdc.gov/vaccines/vpd/shingles/public/shingrix/index.html . Accessed August 25, 2023.